GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC).

Trial Profile

GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms GOAL-ARC
  • Most Recent Events

    • 05 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 19 May 2016 study design has been changed from double blind to open label.
    • 19 May 2016 Planned initiation date changed from 1 Feb 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top